Evidence map›Paper›PMID 29067277›Full record

ArticleWorld journal of clinical oncology2017

Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp.

Nevena Skroza, Ilaria Proietti, Nicoletta Bernardini, Veronica Balduzzi, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Sara Zuber, Giuseppe La Torre, Concetta Potenza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nevena SkrozaDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Ilaria ProiettiDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Nicoletta BernardiniDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Veronica BalduzziDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Alessandra MambrinDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Anna MarchesielloDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Ersilia TolinoDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Sara ZuberDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.
Giuseppe La TorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 04019 Terracina, Italy.
Concetta PotenzaDermatology Unit "Daniele Innocenzi", Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine factors independently influencing response to ingenol mebutate therapy and assess efficacy on clinical setting of non-hypertrophic non-hyperkeratotic actinic keratosis (AK).

methodsConsecutive patients affected by non-hypertrophic non-hyperkeratotic AKs of the face or scalp were enrolled to receive ingenol mebutate 0.015% gel on a selected skin area of 25 cm

resultsA number of 130 patients were enrolled, of which 101 (77.7%) were treated on the face, while 29 (22.3%) on the scalp. The great majority of our study population (

conclusionIngenol mebutate 0.015% gel, when properly applied, is more effective on the face than on the scalp and efficacy is directly associated to LSR score.

Indexed as

Actinic keratosisDermoscopic featureFacial and scalp lesionsIngenol mebutateSkin reactions

Identifiers

PMID29067277
PMCPMC5638716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.